Separation and extraction method of autoactive protein in pleural effusion of cancer patient, method for improving immunity of patient and application of method
The protein in the pleural effusion was recovered through the cold ethanol method, which solved the problem of protein loss in the prior art, achieved efficient, safe and low-cost protein recovery, and improved the patient's nutritional status and immunity.
Patent Information
- Application Number
- CN202411030356.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing protein recovery technology causes a large loss of protein and nutrients when dealing with pleural effusion in cancer patients, affecting the patient's nutritional status and immune function. The existing methods are complex, costly, and cumbersome, making it difficult to promote and apply.
The pleural effusion was mixed with ethanol by cold ethanol, and the pH was adjusted to 6.8~7.2, and centrifuged after refrigeration to obtain the precipitated protein. This method significantly improved the protein recovery and purification efficiency, and simplified the operation steps. Reduced costs.
The cold ethanol method significantly improves the recovery rate of proteins in pleural effusion, retains the biological activity of proteins, reduces the risks of bacteria and viruses, is suitable for medical environments with limited resources, reduces the dependence on exogenous protein supplements, and improves the The patient's nutritional status and immunity.
Smart Images

Figure CN118909027A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of nutrition supply for cancer patients, and in particular, relates to a method for separating and extracting autologous active proteins from pleural effusion of cancer patients, a method for improving the immunity of patients, and applications thereof. Background Art
[0002] Cancer patients often have pleural effusions due to tumor compression, metastasis, or inflammatory response, leading to symptoms such as dyspnea and chest pain. In order to relieve symptoms and alleviate the patient's suffering, pleural effusion aspiration and drainage and other symptomatic treatments are required while treating the primary disease (chemoradiotherapy, targeted therapy). Ultrasound-guided percutaneous thoracentesis and catheter drainage can be performed under the real-time guidance of ultrasound imaging to insert the needle and place the drainage tube. It has the advantages of precision, minimally invasiveness, and significant efficacy. It is widely used in the symptomatic treatment of pleural effusions caused by various diseases. However, while this method effectively achieves lung re-expansion and relieves symptoms such as dyspnea, it also leads to a large loss of protein and other nutrients, affecting the patient's nutritional status and immune function.
[0003] Pleural effusion contains a large amount of protein, including important components such as albumin and immunoglobulin. These proteins are essential for maintaining the normal physiological functions of the body. If these proteins can be effectively recovered during the extraction of pleural effusion, it can not only reduce the loss of nutrients and improve the quality of life of patients, but also reduce the medical system's dependence on such expensive protein supplements. Therefore, developing a method to effectively extract autologous active proteins from pleural effusions of cancer patients is of great significance for improving the treatment effect and prognosis of patients.
[0004] Existing protein recovery technologies mainly include the following:
[0005] 1. Centrifugal concentration method: Use a high-speed centrifuge to centrifuge the pleural effusion sample to precipitate macromolecules such as proteins, and then collect the precipitate. This method is relatively simple, but has high requirements for equipment and is prone to protein denaturation during operation.
[0006] 2. Ultrafiltration: Utilize the selective permeability of ultrafiltration membrane to allow small molecules and water in pleural effusion to pass through the membrane, while retaining large molecular proteins. This method is highly efficient and can be performed at low temperatures, reducing the risk of protein denaturation, but the protein recovery is low and the operation is cumbersome and difficult to promote and apply.
[0007] 3. Gel filtration method: Use gel filtration columns to separate pleural effusions and recover proteins in different grades according to their molecular sizes. This method is suitable for large-scale protein recovery, but the equipment is complex and the operation time is long.
[0008] 4. Electrophoresis: Use electric field to separate proteins according to their charge and molecular weight, and then recover the target protein. This method has high resolution, but requires high operating technology and is suitable for small-scale protein recovery under laboratory conditions.
[0009] 5. Immunoprecipitation: Specific antibodies are used to bind to the target protein to form a precipitate, and then the precipitate is collected. This method is highly specific and suitable for recovering specific types of proteins, but it is expensive and requires corresponding antibody preparation.
[0010] However, none of the above protein recovery methods have been used to recover active proteins from pleural effusion. The autologous recovery of active proteins from pleural effusion of cancer patients has certain particularities:
[0011] 1. High levels of tumor markers: Pleural effusion often contains high concentrations of tumor markers (such as carcinoembryonic antigen, cancer antigen 125, etc.), which can be used for disease monitoring and treatment effect evaluation.
[0012] 2. Inflammation and immune response: Cancer-related pleural effusions are often accompanied by significant inflammatory responses, containing a large number of cytokines and inflammatory mediators. These components may affect the recovery and purification process of proteins.
[0013] 3. Heterogeneity: The composition of pleural effusions can vary significantly depending on the cancer type, stage, and individual differences among patients, making standardized processing and recovery processes challenging.
[0014] 4. Potential for therapeutic applications: The recovered active protein may have therapeutic potential, such as for use in immunotherapy or as a carrier of therapeutic agents.
[0015] 5. Individualized treatment of patients: Autologous recovered active proteins can be used for individualized treatment of patients, providing more precise and targeted treatment plans, which is of great significance in the field of personalized medicine.
[0016] In summary, considering the value of protein in pleural effusion and its importance to patient health, it is particularly urgent and beneficial to develop an efficient protein recovery technology. Summary of the invention
[0017] The purpose of this application is to provide a method for separating and extracting autologous active proteins from pleural effusion of cancer patients, a method for improving the immunity of patients and their applications, aiming to solve the problem that the existing methods for treating pleural effusion lead to a large loss of protein and other nutrients, affecting the nutritional status and immune function of patients.
[0018] In order to achieve the above application purpose, the technical solution adopted in this application is as follows:
[0019] In a first aspect, the present application provides a method for separating and extracting autologous active proteins from pleural effusion of cancer patients, comprising:
[0020] Cool the pleural effusion and ethanol to ≤4°C;
[0021] The pleural effusion and ethanol are mixed and stirred, wherein the volume of the ethanol is 50% to 70% of the volume of the pleural effusion;
[0022] Adjust the pH value of the system to 6.8-7.2, and then refrigerate in an environment with a temperature of ≤4°C for 2-4 hours;
[0023] The refrigerated system is centrifuged to obtain precipitated protein.
[0024] As a possible design, the volume of the ethanol is 60% to 70% of the volume of the pleural effusion.
[0025] As a possible design, the temperature of the pleural effusion and ethanol are both cooled to -10 to 4°C.
[0026] As a possible design, pleural fluid and ethanol are mixed as follows:
[0027] Ethanol was added to the pleural effusion at a rate of approximately 5-10% of the effusion volume per minute.
[0028] As a possible design, the pH value is 6.8-7.0.
[0029] As a possible design, the separation and extraction method further includes pre-treating the pleural effusion before cooling, and the pre-treatment includes filtration or centrifugation.
[0030] As a possible design, the separation and extraction method further comprises purifying the obtained protein, and the purification comprises filtering with filter paper or microporous filter membrane.
[0031] As a possible design, the centrifugal speed in the centrifugal separation is 2000-3000 rpm, and the separation time is 3-6 minutes.
[0032] In a second aspect, the present application provides a method for improving a patient's immunity, wherein the protein obtained by the separation and extraction method is injected back into the patient's body.
[0033] The beneficial effects of the present invention are:
[0034] 1. High recovery rate: Cold ethanol precipitation conditions (different ethanol concentrations) can significantly improve the recovery rate of effective proteins in pleural effusion, minimize protein loss, and retain more valuable bioactive substances.
[0035] 2. Good protein integrity and activity retention: Protein precipitation under low temperature conditions helps reduce the risk of protein inactivation due to thermal denaturation, thereby better preserving the original structure and biological function of the protein.
[0036] 3. Improved safety: Cold ethanol treatment can effectively remove potential pathogens such as bacteria and viruses in pleural effusion, improve the safety of recovered proteins, and provide a guarantee for subsequent clinical applications.
[0037] 4. Easy operation and cost-effectiveness: This method is simple to operate and does not require complex equipment or high operating costs. Compared with other protein separation technologies, it has obvious cost advantages and is particularly suitable for medical environments with limited resources.
[0038] 5. Environmentally friendly: Compared with chemical methods, the cold ethanol method uses less or no harmful chemical reagents, and the treatment process has less impact on the environment. It is a more environmentally friendly protein recovery method.
[0039] 6. Wide applicability: This technology is not only suitable for the recovery of proteins in pleural effusion, but can also be used for the separation and purification of proteins in other body fluids or biological samples, and has broad application prospects.
[0040] 7. Improve patient treatment experience and prognosis: By effectively recovering and reusing protein in pleural effusion, the loss of protein in the patient's body is reduced, which helps to improve the patient's nutritional status and immunity, thereby potentially improving the treatment effect and the patient's quality of life.
[0041] 8. Reduce medical costs: By reducing dependence on exogenous proteins (such as synthetic albumin), treatment costs are reduced, which is economically beneficial to both the medical system and patients.
[0042] In summary, the cold ethanol method is expected to bring significant technical improvements and multi-faceted benefits in recovering effective proteins in pleural effusions, which will play an important role in promoting clinical treatment and patient recovery. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0044] Figure 1 This is a recovery distribution diagram of pleural effusion protein of lung cancer patients at different ethanol concentrations in Example 1 of the present application;
[0045] Figure 2 is the pleural effusion protein distribution diagram of the lung cancer patient in Example 1 of the present application;
[0046] Figure 3 This is a graph showing the results of pleural effusion cytotoxicity testing in a lung cancer patient in Example 1 of the present application;
[0047] Figure 4 This is a recovery rate distribution diagram of pleural effusion protein of nasopharyngeal carcinoma patients at different ethanol concentrations in Example 2 of the present application;
[0048] Figure 5 This is the protein distribution diagram of the pleural effusion of a nasopharyngeal carcinoma patient in Example 2 of the present application;
[0049] Figure 6 This is a graph showing the results of cytotoxicity testing of pleural effusion in patients with nasopharyngeal carcinoma in Example 2 of the present application;
[0050] Figure 7 This is a recovery rate distribution diagram of pleural effusion protein of a patient with mediastinal tumor at different ethanol concentrations in Example 3 of the present application;
[0051] Figure 8 is the pleural effusion protein distribution diagram of the patient with mediastinal tumor in Example 3 of the present application;
[0052] Fig. 9 This is a graph showing the results of pleural effusion cytotoxicity testing in patients with mediastinal tumors in Example 3 of the present application;
[0053] Fig.10 This is a recovery rate distribution diagram of pleural effusion protein of patients with lung metastatic cancer in Example 4 of the present application at different ethanol concentrations;
[0054] Fig.11 This is the protein distribution diagram of the pleural effusion of a patient with lung metastasis cancer in Example 4 of the present application;
[0055] Fig.12 This is a graph showing the results of pleural effusion cytotoxicity testing of patients with lung metastasis cancer in Example 4 of the present application. DETAILED DESCRIPTION
[0056] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.
[0057] In this application, the term "and / or" describes the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can mean: A exists alone, A and B exist at the same time, and B exists alone. A and B can be singular or plural. The character " / " generally indicates that the associated objects are in an "or" relationship.
[0058] In this application, "at least one" means one or more, and "plurality" means two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b, or c", or "at least one of a, b, and c" can all mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, c can be single or multiple, respectively.
[0059] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.
[0060] The terms used in the embodiments of the present application are only for the purpose of describing specific embodiments, and are not intended to limit the present application. The singular forms "a", "said" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.
[0061] The weight of the relevant components mentioned in the embodiment description of the present application can not only refer to the specific content of each component, but also represent the proportional relationship between the weights of the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the embodiment description of the present application, it is within the scope disclosed in the embodiment description of the present application. Specifically, the mass described in the embodiment description of the present application can be a mass unit known in the chemical industry such as μg, mg, g, kg, etc.
[0062] The term "PET" is the abbreviation of "Polyethylene terephthalate", which means polyethylene terephthalate; the term "PU" is the abbreviation of "polyurethane", which means polyurethane material and is the abbreviation of polyurethane.
[0063] Pleural effusion contains a large amount of protein, including albumin, immunoglobulin and other important components. These proteins are essential for maintaining the normal physiological functions of the body, but there is currently no protein recovery technology applied to pleural effusion.
[0064] In view of the above problems, in a first aspect, the present application provides a method for separating and extracting autologous active proteins from pleural effusion of cancer patients, comprising the following steps:
[0065] S1. Cool the temperature of pleural effusion and ethanol to ≤4°C to minimize the possibility of protein denaturation in pleural effusion. Considering the balance between energy saving and protein denaturation, the temperature is preferably -10 to 4°C.
[0066] S2. mixing and stirring the pleural effusion and ethanol, wherein the volume of the ethanol is 50% to 70% of the volume of the pleural effusion, preferably 60% to 70%;
[0067] Specifically, the step may be: slowly and evenly adding ethanol into the pleural effusion, wherein the amount of ethanol added per minute is approximately 5-10% of the volume of the effusion.
[0068] S3. Adjust the pH value of the system to 6.8-7.2, and then refrigerate at a temperature of ≤4°C for 2-4 hours;
[0069] The pH value is preferably 6.8 to 7.0. The temperature of the refrigerated environment is preferably -10 to 4°C. The refrigerated time is preferably 3 hours.
[0070] S4. Centrifuge the refrigerated system to obtain precipitated protein.
[0071] In this step, the centrifugal speed in the centrifugal separation is 2000-3000 rpm, preferably 2300-2600 rpm, and the separation time is 3-6 min, preferably 5 min.
[0072] Before the processing in step S1, the pleural effusion may be pre-treated, specifically by filtration or centrifugation, the purpose of which is to remove large particle impurities and cell components in the pleural effusion to reduce interference in subsequent steps.
[0073] After the treatment in step S4, the obtained protein may be purified. The purification includes filtering with filter paper or microporous filter membrane to further improve the purity of the protein.
[0074] In a second aspect, the present invention provides a method for improving a patient's immunity, wherein the protein obtained by the aforementioned separation and extraction method is injected back into the patient's body.
[0075] Through the above-mentioned operation process, effective protein can be effectively recovered from the patient's pleural effusion. This technical solution not only improves the efficiency and safety of protein recovery, but also simplifies the operation steps and reduces costs. It has important practical significance for clinical applications.
[0076] The following describes the invention in conjunction with specific embodiments.
[0077] Example 1
[0078] The pleural effusion involved in this embodiment comes from a lung cancer patient.
[0079] This embodiment discloses a method for separating and extracting autologous active proteins from pleural effusion of cancer patients, comprising the following steps:
[0080] S1. Select a sample from a patient with pleural effusion caused by lung cancer to ensure the diversity and representativeness of the sample, and remove large particle impurities and cellular components by filtration or centrifugation to reduce interference in subsequent steps.
[0081] S2. The samples were randomly divided into 11 groups and treated with different ethanol concentrations (10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%). A control group without ethanol treatment was set up. The treated pleural effusion samples and ethanol were precooled to 4°C to maintain low temperature conditions.
[0082] S3. Slowly add pre-cooled ethanol to the pleural effusion while gently stirring to promote mixing. The volume of pre-cooled ethanol is 60% of the volume of the pleural effusion.
[0083] S4. Adjust the pH value of the system to 7.0, and then refrigerate the pleural effusion with added ethanol at 4°C for 4 hours to promote complete precipitation of the protein.
[0084] S5. The refrigerated system is centrifuged to separate the precipitated protein and the supernatant to obtain the precipitated protein. The centrifugal speed is 2500 rpm and the time is 5 min.
[0085] S6. Collect the precipitated protein and filter it through a 0.45 μm pore size polyvinylidene fluoride membrane (PVDF) to further improve the purity of the protein due to its strong chemical resistance and low protein adsorption.
[0086] The concentration of the protein obtained in step S6 is measured as follows:
[0087] The protein concentration was determined by the Bicinchoninic Acid (BCA) method. The total protein was mixed with SDS-PAGE sample loading buffer (Beyotime, P0015L, China), boiled at 100°C for 10 min for denaturation, and then separated by SDS-PAGE. The cytotoxicity and biosafety of the extracted protein were observed at the same time. The results are as follows:
[0088] (1) Recovery rate: Figure 1As shown, among the experimental groups, the 60% ethanol concentration group showed the highest protein recovery rate, reaching an average of 79.7%, while the control group had almost no protein recovery.
[0089] (2) Protein purity: Protein distribution was analyzed by SDS-PAGE. Figure 2 As shown, Figure 2 Samples 1-4 are protein components extracted from the pleural effusion of the same lung cancer patient (repeated 4 times), and control is the pleural effusion sample of the patient that has not been treated with ethanol.
[0090] (3) Safety test: After cytotoxicity test, the results are as follows Figure 3 As shown, protein samples in all experimental groups showed good safety.
[0091] Example 2
[0092] Compared with Example 1, this embodiment has the following differences:
[0093] The pleural effusion involved in this example comes from a patient with nasopharyngeal carcinoma. The remaining experimental methods are the same as those in Example 1.
[0094] The results are as follows:
[0095] (1) Recovery rate: Figure 4 As shown, among the experimental groups, the 70% ethanol concentration group showed the highest protein recovery rate, reaching an average of 81.6%, while the control group had almost no protein recovery.
[0096] (2) Protein purity: Protein distribution was analyzed by SDS-PAGE. Figure 5 As shown, Figure 5 Samples 1-4 are protein components extracted from the chest of the nasopharyngeal carcinoma patient (repeated 4 times), and control is the pleural effusion sample of the patient that has not been treated with ethanol.
[0097] (3) Safety test: After cytotoxicity test, the results are as follows Figure 6 As shown, protein samples in all experimental groups showed good safety.
[0098] Example 3
[0099] Compared with Example 1, this embodiment has the following differences:
[0100] The pleural effusion involved in this example comes from a patient with a mediastinal tumor. The remaining experimental methods are the same as those in Example 1.
[0101] The results are as follows:
[0102] (1) Recovery rate: Figure 7As shown, in the experimental groups, the 60% and 70% ethanol concentration groups showed similarly high protein recovery rates, reaching an average of 84.2% and 85.6%, respectively, while the control group had almost no protein recovery.
[0103] (2) Protein purity: Protein distribution was analyzed by SDS-PAGE, such as Figure 8 As shown, Figure 8 Samples 1-4 are protein components extracted from the chest of the patient with mediastinal tumor (repeated 4 times), and control is the pleural effusion sample of the patient without ethanol treatment.
[0104] (3) Safety test: After cytotoxicity test, the results are as follows Fig. 9 As shown, protein samples in all experimental groups showed good safety.
[0105] Example 4
[0106] Compared with Example 1, this embodiment has the following differences:
[0107] The pleural effusion involved in this example comes from a patient with lung metastatic cancer. The remaining experimental methods are the same as those in Example 1.
[0108] The results are as follows:
[0109] (1) Recovery rate: Fig.10 As shown, among the experimental groups, the 50% ethanol concentration group showed the highest protein recovery rate, reaching an average of 84.3%, while the control group had almost no protein recovery.
[0110] (2) Protein purity: Protein distribution was analyzed by SDS-PAGE. Fig.11 As shown, Fig.11 Samples 1-4 are protein components extracted from the chest of the patient with lung metastasis (repeated 4 times), and control is a pleural effusion sample of the patient that has not been treated with ethanol.
[0111] (3) Safety test: After cytotoxicity experiments, such as Fig.12 As shown, protein samples in all experimental groups showed good safety.
[0112] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.
Claims
1. A method for separating and extracting autologous active proteins from pleural effusion of cancer patients, characterized in that: The separation and extraction method comprises: Cool the pleural effusion and ethanol to ≤4°C; The pleural effusion and ethanol are mixed and stirred, and the volume of ethanol is 50% to 70% of the volume of the pleural effusion; Adjust the pH value of the system to 6.8-7.2, and then refrigerate at a temperature of ≤4°C for 2-4 hours; The refrigerated system is centrifuged to obtain precipitated protein.
2. The method for separating and extracting autologous active protein from pleural effusion of cancer patients according to claim 1, characterized in that: The volume of the ethanol is 60% to 70% of the volume of the pleural effusion.
3. The method for separating and extracting autologous active protein from pleural effusion of cancer patients according to claim 1, characterized in that: The temperatures of the pleural effusion and ethanol are both cooled to -10~4°C.
4. The method for separating and extracting autologous active protein from pleural effusion of cancer patients according to claim 1, characterized in that: Mix pleural fluid and ethanol as follows: Add ethanol to the pleural effusion. The speed of adding ethanol should be slow and uniform to avoid protein denaturation or incomplete precipitation caused by adding too quickly. Dropping speed: The amount of ethanol added per minute is about 5-10% of the volume of the effusion.
5. The method for separating and extracting autologous active protein from pleural effusion of cancer patients according to claim 1, characterized in that: The pH value is between 6.8 and 7.
0.
6. The method for separating and extracting autologous active protein from pleural effusion of cancer patients according to claim 1, characterized in that: The separation and extraction method further comprises pre-treating the pleural effusion before cooling, and the pre-treatment comprises filtering or centrifuging.
7. The method for separating and extracting autologous active protein from pleural effusion of cancer patients according to claim 1, characterized in that: The separation and extraction method further comprises purifying the obtained protein, and the purification comprises filtering with filter paper or microporous filter membrane.
8. The method for separating and extracting autologous active protein from pleural effusion of cancer patients according to claim 1, characterized in that: The centrifugal speed in the centrifugal separation is 2000-3000 rpm, and the separation time is 3-6 min.
9. A method for improving a patient's immunity, characterized in that: The protein obtained by the separation and extraction method according to any one of claims 1 to 8 is returned to the patient's body.
10. Use of the separation and extraction method according to any one of claims 1 to 8 in the separation and purification of proteins.
Citation Information
Patent Citations
Method for concentration of low-molecular-weight proteins and peptides in body fluid sample
CN101821618A
Protein markers for the diagnosis and prognosis of ovarian and breast cancer
US20080213907A1
Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
WO2003034982A2
Protein purification
WO2008068455A1
